The DOI matches its Crossref record.
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer
Open accessAbstract
BACKGROUND: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined. METHODS: We randomly assigned 1060 women with axillary-node-negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St. Gallen criteria) to treatment with TAC or FAC every 3 weeks for six cycles after surgery. The primary end point was disease-free survival after at least 5 years of follow-up. Secondary end points included overall survival and toxicity. RESULTS: At a median follow-up of 77 months, the proportion of patients alive and disease-free was higher among the 539 women in the TAC group (87.8%) than among the 521 women in the FAC group (81.8%), representing a 32% reduction in the risk of recurrence with TAC (hazard ratio, 0.68; 95% confidence interval [CI], 0.49 to 0.93; P=0.01 by the log-rank test). This benefit was consistent, regardless of hormone-receptor status, menopausal status, or number of high-risk factors. The difference in survival rates (TAC, 95.2%; FAC, 93.5%) was not significant (hazard ratio, 0.76; 95% CI, 0.45 to 1.26); however, the number of events was small (TAC, 26; FAC, 34). Rates of grade 3 or 4 adverse events were 28.2% with TAC and 17.0% with FAC (P<0.001). Toxicity associated with TAC was diminished when primary prophylaxis with granulocyte colony-stimulating factor was provided. CONCLUSIONS: As compared with adjuvant FAC, adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer. (Funded by GEICAM and Sanofi-Aventis; ClinicalTrials.gov number, NCT00121992.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
Progress in adjuvant chemotherapy for breast cancer: an overview
Anampa, J., Makower, D., & Sparano, J. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0439-8 · Cited by 373
Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mds636 · Cited by 117
Metadata
- Authors
- Martín, M., Seguí, M. A., Antón, A., Ruiz, A., Ramos, M., Adrover, E., Aranda, I., Rodríguez-Lescure, A., Große, R., Calvo, L., Barnadas, A., Isla, D., Martinez del Prado, P., Ruiz Borrego, M., Zaluski, J., Arcusa, A., Muñoz, M., López Vega, J. M., Mel, J. R., Munarriz, B., Llorca, C., Jara, C., Alba, E., Florián, J., Li, J., López García-Asenjo, J. A., Sáez, A., Rios, M. J., Almenar, S., Peiró, G., & Lluch, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-02
- Volume
- 363
- Issue
- 23
- Pages
- 2200-2210
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2084370697
- Cited by
- 209
- References
- 0
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. https://app.cochat.ai/papers/10.1056/nejmoa0910320
- The paper
- Martín, M., Seguí, M. A., Antón, A., Ruiz, A., Ramos, M., Adrover, E., Aranda, I., Rodríguez-Lescure, A., Große, R., Calvo, L., Barnadas, A., Isla, D., Martinez del Prado, P., Ruiz Borrego, M., Zaluski, J., Arcusa, A., Muñoz, M., López Vega, J. M., Mel, J. R., . . . Lluch, A. (2010). Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa0910320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.